NovaBridge Biosciences (NBP) AI Stock Analysis

NovaBridge Biosciences, formerly known as I-Mab, is a biotechnology company that researches and develops immuno-oncology agents for cancer treatment in the United States. Operating through Oncology and Ophthalmology segments, its clinical pipeline features givastomig, a CLDN18.2 bispecific antibody in Phase 2 testing with nivolumab and chemotherapy for gastric cancer, and VIS-101, a VEGF-A × ANG-2 bispecific biologic in Phase 2 trials for wet age-related macular degeneration and diabetic macular edema. It also develops ragistomag in Phase 1 trials for solid tumors. The company maintains collaboration and licensing agreements with Bristol Myers Squibb, AbbVie Ireland Unlimited Company, and AskGene.

Revenue declined at a 5-year CAGR of -39.2% from FY2018 to FY2023. After peaking at $1.54B with net income of $470.9M in FY2020, revenue dropped to $88.0M in FY2021 and -$10.7M in FY2022. In FY2023, revenue was $4.5M, operating margin was -11395.1%, and net income was -$1.47B, driven in part by $114.4M in research and development expenses. For the trailing twelve months ending June 30, 2026, revenue stood at $0 with an operating margin of 0.0% and an EPS of -$0.69. For the current fiscal year ending December 31, 2026, consensus estimates project $0 in revenue and an EPS of -$0.91.

As of June 30, 2026, NovaBridge Biosciences held $190.8M in cash and short-term investments against $4.5M in total debt, resulting in net cash of $186.4M. Total assets stood at $231.5M and shareholders' equity was $201.1M, supporting a current ratio of 7.64 and a debt-to-equity ratio of 0.02. In FY2023, free cash flow was -$73.0M and operating cash flow was -$72.9M. In FY2025, capital expenditures totaled $7,000, while the company's share count increased 47.4% over five years.

At a last close of $1.26, NovaBridge Biosciences has a market capitalization of $146.2M and an enterprise value of -$10.0M. The stock trades at a price-to-book ratio of 0.9x and a price-to-sales multiple of 25.4x, which is above the 4.1x median of its US-listed Healthcare peers. Its forward price-to-earnings ratio is 2.7x, compared to the peer median of 17.3x. Over the past year, NBP shares fell 80.8%, trailing the 16.8% return of the S&P 500 (SPY). Over five years, the stock declined 98.1% while SPY gained 83.0%.

Wall Street coverage consists of 2 Strong Buy ratings, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell recommendations. The mean price target is $9.00, representing an upside of 614.3% over the last close of $1.26. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.91 on $0 in revenue. For the following fiscal year, the consensus EPS estimate is -$0.63 with projected revenue of $0. Over the last four quarters, the company has beaten EPS expectations 2 times.

This page is an AI-written research summary of NovaBridge Biosciences (NBP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NBP income statement, NBP balance sheet, NBP key metrics, NBP analyst forecast, NBP chart. See the NBP stock overview for the latest quote and news.